CUE: Cue Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Cue Biopharma reported Q3 2026 results: revenue $0.1M, net loss $50.0M, R&D expenses $17.0M, and cash $57.9M. The company expects a $3.0M payment in Q4 2026. CUE-401 began clinical trials, and FDA cleared CUE-221 IND application.
How this was made
The 30-second read
Why it matters
The filing updates the company’s near-term financial runway (cash $57.9M) and highlights a larger quarterly net loss alongside early clinical momentum (CUE-401 first-in-human dosing) and an FDA IND clearance (CUE-221 for food allergy).
Market read
Traders get a fresh quarterly P&L and cash update plus near-term catalyst timing (ImmunoScape payment in Q4) that can influence valuation and financing-risk expectations.
What to watch
Non-cash stock compensation inflated the loss; traders may focus more on cash burn trajectory and the probability/timing of future milestone payments rather than GAAP net loss alone.
Background
The article summarizes Cue Biopharma’s SEC Form 8-K for Q3 2026 results, including financial statements and key clinical/regulatory updates.
Ticker impact
Cue Biopharma reported Q3 revenue of $0.1M (down from $2.1M) and net loss of $50.0M, citing higher R&D and stock comp.
Likely near-term pressure as investors weigh the larger loss and revenue decline against early clinical progress and expected ImmunoScape cash.
The filing provides specific quarterly P&L and cash figures plus concrete clinical/regulatory milestones, making the risk-reward update actionable for traders.
Market effects
Biotech investors may recalibrate risk appetite for pre-revenue or early-stage programs when quarterly cash burn and collaboration revenue weaken.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited, as the disclosure is company-specific and not tied to a global macro or cross-border regulatory event.
Counterpoint
The revenue drop may be timing-related under the Boehringer Ingelheim collaboration, while the company’s cash balance and upcoming ImmunoScape installment reduce immediate financing risk.
Key entities
- companyCue Biopharma Inc.
Subject of the SEC Form 8-K, reporting Q3 2026 financial results and clinical/regulatory milestones.
- clinical_programCUE-401
Began first-in-human dosing, reaching a key 2026 milestone per the filing summary.
- clinical_programCUE-221
FDA cleared the IND application for food allergy per the filing summary.
- collaboration_paymentImmunoScape payment
Expected $3.0M in Q4 2026 as part of a total $5.5M payable in installments.
- partnerBoehringer Ingelheim
Collaboration referenced as the source of licensing revenue that declined in Q3.


